BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Truffle Capital Debuts ABIVAX, A Company Focused On Vaccines and Antivirals


2/12/2014 9:38:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Creation of ABIVAX - a Leader in Therapeutic Vaccines and the First French Company to Sign an Exclusive Partnering Agreement with Cuba in Healthcare

Truffle Capital founded ABIVAX by merging three French companies and building on a collaboration with the Cuban Center for Genetic Engineering and Biotechnology

PARIS-Truffle Capital has announced the creation of Paris-based ABIVAX in collaboration with the Cuban Center for Genetic Engineering and Biotechnology (CIGB). This is the first ever start-up launched on the basis of a Euro-Cuban R&D collaboration. The goal of ABIVAX is to become a global leader in therapeutic vaccines and antivirals, leveraging both its existing product pipelines and future acquisitions that are currently in negotiations.

ABIVAX specializes in therapeutic vaccines and antivirals, combining the technologies and the product portfolios of three French biotech companies financed by Truffle Capital (Wittycell, Splicos and Zophis). An exclusive partnership agreement with the CIGB has been approved by the Cuban government and will further enrich the portfolio. The CIGB is the largest subsidiary under BioCubaFarma that specializes in the discovery, development and production of vaccines and antivirals. ABIVAX already possesses several key assets including complementary technology platforms, a high-value product portfolio and an experienced top management team.

The most advanced products in the portfolio of ABIVAX target a variety of major medical needs. They include: a therapeutic vaccine for chronic hepatitis B (which leads to cirrhosis and liver cancer) from CIGB and Wittycell; a novel anti-viral drug for AIDS from Splicos, an anti-HPV therapeutic vaccine to treat, without surgery, uterine cervix dysplasia and prevent the emergence of cancer from Wittycell, a novel adjuvant to boost NKT and B cell response from Wittycell. Thus, ABIVAX already has two therapeutic vaccines in development, one in a Phase IIb clinical trial in patients with chronic hepatitis B, and the other one expected to enter into a Phase I clinical trial in 2015 for the treatment of chronic infection with human papilloma virus and cervical dysplasia (an early stage in cervical cancer). The adjuvant is in Phase I clinical studies. In the field of AIDS, the company's first antiviral drug displays a novel mechanism of action, which might translate into a long-term effect on viral load reduction. It is scheduled to enter clinical trials in Q1 2014. Additional therapeutic vaccines are in preclinical development.

www.abivax.com
www.truffle.com
www.cigb.edu.cu

Contacts

Alize RP
Caroline Carmagnol: +33 664-189-959
caroline@alizerp.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES